Entrada Therapeutics, Inc. (TRDA) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
TRDA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TRDA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 83.9% | -613.7% | -565.5% |
| 2024 | 100.0% | 22.3% | 31.1% |
| 2023 | 100.0% | -2.5% | -5.2% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export TRDA earnings history in CSV or JSON format
Free sign-in required to download data
Entrada Therapeutics, Inc. (TRDA) Earnings Overview
As of May 8, 2026, Entrada Therapeutics, Inc. (TRDA) reported trailing twelve-month net income of -$166M, reflecting -306.5% year-over-year growth. The company earned $-3.97 per diluted share over the past four quarters, with a net profit margin of -565.5%.
Looking at the long-term picture, TRDA's historical earnings data spans multiple years. The company achieved its highest annual net income of $66M in fiscal 2024.
Entrada Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR (-$301M net income, -0.2% margin), NTLA (-$413M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), TRDA has room to improve margins relative to the peer group. Compare TRDA vs ARWR →
TRDA Earnings vs Peers
Earnings metrics vs comparable public companies
TRDA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$144M | -319.0% | -$156M | $-3.47 | -565.5% | -613.7% |
| 2024 | $66M | +1081.7% | $47M | $1.68 | 31.1% | 22.3% |
| 2023 | -$7M | +92.9% | -$3M | $-0.20 | -5.2% | -2.5% |
| 2022 | -$95M | -84.9% | -$97M | $-2.79 | - | - |
| 2021 | -$51M | -92.9% | -$51M | $-1.60 | - | - |
| 2020 | -$27M | -470.5% | -$27M | $-0.84 | - | - |
| 2019 | -$5M | - | -$12M | $-4.44 | - | - |
See TRDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TRDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TRDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTRDA — Frequently Asked Questions
Quick answers to the most common questions about buying TRDA stock.
Is TRDA growing earnings?
TRDA EPS fell to $-3.97, with earnings declining -306.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-166M.
What are TRDA's profit margins?
Entrada Therapeutics, Inc. net margin is -565.5%, with operating margin at -613.7%. Below-average margins reflect competitive or cost pressures.
How consistent are TRDA's earnings?
TRDA earnings data spans 2019-2025. The declining earnings trend is -306.5% YoY. Historical data enables comparison across business cycles.